Kidney diseases and NOAC therapy: Is there a light at the end of the tunnel?

Int J Cardiol. 2017 Jun 1:236:162-163. doi: 10.1016/j.ijcard.2017.01.066. Epub 2017 Jan 10.

Authors

Matthias Hammwöhner¹, Andreas Goette²

Affiliations

¹ Dept. of Cardiology and Intensive Care Medicine, St. Vincenz-Krankenhaus, Paderborn, Germany; Working Group: Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg, Germany.
² Dept. of Cardiology and Intensive Care Medicine, St. Vincenz-Krankenhaus, Paderborn, Germany; Working Group: Molecular Electrophysiology, University Hospital Magdeburg, Magdeburg, Germany. Electronic address: andreas.goette@vincenz.de.

PMID: 28096038
DOI: 10.1016/j.ijcard.2017.01.066

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anticoagulants*
Atrial Fibrillation*
Humans
Kidney Diseases

Substances

Anticoagulants